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Abstract
Over 50% of patients diagnosed with non-small-
cell lung cancer (NSCLC) are 65 years old while 30% 
exceed 70 years old. Comparing elderly patients 
to their younger counterpart they poorly tolerate 
chemotherapy due to progressive reduction of organ 
function and age-related co-existing pathologies. 
Due to this reason elderly are usually excluded from 
platinum-based chemotherapy, which still represent 
the standard of care for advanced NSCLC. In every-day 
practice, single-agent schedule with a third-generation 
drug is the recommended option for elderly patients 
with advanced NSCLC. A modest increase in toxicity for 
elderly patients has been demonstrated by subgroup 
analyses concluding for platinum-based combination 
chemotherapy being similar in young patients and fit 
elderly. Even though the cited evidence, feasibility of 
chemotherapy based on platinum remains an open 
question. Prospective randomised trials are warranted 
in order to change guide lines and give the clinicians 
a new therapeutic option. Recent emerging role of 
molecular target in selecting patients for new targeted 
therapies suggest dedicated trials for elderly patients. 
The same is for more accurate evaluation of elderly 
patients with increasing evidence for a comprehensive 
geriatric assessment as a valid tool for customized 
treatment in NSCLC elderly patients. Suitable evidences 
for the treatment of elderly patients affected by 
advanced NSCLC together with more appropriate and 
validated tools for patients selection are reviewed along 
the manuscript.
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Core tip: Due to progressive ageing of population in the 
next few years a consistent proportion of non-small-cell 
lung cancer (NSCLC) patients will be diagnosed over 
the age of 70 years old. Guide lines indications together 
with results from most recent phase Ⅲ trials dedicated 
to elderly patients are discussed along the review. 
Special attention has been deserved to toxicity profile. 
Recent emerging role of molecular target in selecting 
patients for new targeted therapies suggest dedicated 
trials as for more accurate evaluation with increasing 
evidence for a comprehensive geriatric assessment as 
a valid tool for treatment selection in NSCLC elderly 
patients.
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INTRODUCTION
Non-small-cell lung cancer (NSCLC) still represents 
the most frequent cause of cancer-related deaths in 
Europe and many western countries. Median age at 
diagnosis of NSCLC is around 70 years old with 50% 
and more diagnosed over 65 and 30% over 70[1,2]. 
Continuous shifting toward an older population will 
cause oncologists seeing more elderly patients with 
lung cancer in years to come. 
The highest percentage of patients presents with 
metastatic disease at diagnosis with chemotherapy 
standing for the gold standard of management. It is 
demonstrated that many older patients with metastatic 
NSCLC are not treated due to many reasons[3,4]. Aging 
is cause of physiological changes in organ functions, 
as for example renal and liver function. Co-morbidities 
and and consequent drugs intake which may condition 
chemotherapy administration and toxicity profile[5]. An 
immediate consequence is a sort of under-treatment 
for this setting of patients[6]. 
It is known that these patients are not candidated 
to clinical trials causing difficulty in reaching evidence-
based clinical recommendation. In current clinical 
practice the choice of treatment is still very often based 
on a old-believe that cancer in older people behave in 
a less aggressive manner[7]. 
A significant difference has been documented 
on a survey which considered trials for cancer drug 
registration from 1995 to 2002 with only 35% of 
elderly patients enrolled on clinical trials[8]. Such a 
discordance can greatly affect the reproducibility of 
trial results.
Chronological age should be no more considered 
the correct parameter on which candidate patients 
to receive specific treatment. Biological age should 
be defined through laboratory tests and geriatric 
assessment evaluation. However chronological age 
still represent a reference for clinical trials: 70 years 
old is considered a reasonable cut-off considering the 
incidence of age-related variations starts to increase 
after the age of 70[9]. Many evidences suggest an 
advanced median age of elderly patients in dedicated 
trials with milder reported toxicity respect to that 
reported in age-unspecified studies[10]. 
SINGLE-AGENT CHEMOTHERAPY
The ELVIS trial was the first phase Ⅲ trial conducted 
in advanced NSCLC patients aged ≥ 70 years old. 
Patients were randomized to receive vinorelbine at a 
dose of 30 mg/m2 on days 1 and 8 or best supportive 
care. Advantage in term of survival and increased 
quality of life (QoL) were demonstrated for vinorelbine 
arm[11].
Regarding the role of gemcitabine in the treatment 
of elderly patients affected by advanced NSCLC many 
specifically addressed phase Ⅱ trials confirmed its 
interesting role with an overall response rates (ORR) 
of 18% to 38% and MST of 6.8 to 9 mo. Toxicity 
was mild with only sporadic grade 3 to 4 hematologic 
toxicities in two of them[12-15].
Other specific trials demonstrated satisfying data 
regarding both activity and feasibility for paclitaxel and 
docetaxel: ORR 3%-23% and MST 6.8-10.3 mo[16]. 
Overall response rate (ORR) and median survival time 
(MST) were as follow: 3%-23% and 6.8-10.3 mo, 
respectively, with acceptable toxicity[16-21]. 
When docetaxel was compared to vinorelbine in a 
randomized phase Ⅲ trial no significant difference in 
MST was encountered, while longer progression-free 
survival (PFS) and higher ORR were demonstrated for 
docetaxel[22].
NON-PLATINUM-BASED 
POLICHEMOTHERAPY
Among non-platinum-based regimen the association of 
gemcitabine plus vinorelbine has been widely studied. 
At least two phase Ⅲ trials compared the combination 
with single agent schedule. Frasci et al[23] obtained 
survival advantage for combination respect to single 
agent in term of MST and ORR. 
The Multicenter Italian Lung cancer in the Elderly 
Study (MILES) trial with its 700 elderly patients affected 
by advanced NSCLC, represents a milestone in this 
setting. Patients were randomised to receive vinorelbine 
or gemcitabine or combination. Considering ORR, time 
to progression (TTP), MST or QoL no advantage was 
demonstrated over single-agent therapy in favour of 
combination therapy. Single-agent therapy confirmed 
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its role in this setting[24].
Hainsworth et al[25] demonstrated that docetaxel plus 
gemcitabine vs weekly docetaxel alone did not improve 
survival in a population of 350 accrued and randomized 
elderly patients affected by advanced NSCLC. Moreover, 
in these two trials the doublet was slightly more toxic 
than single agent treatment[25] (Table 1).
PLATINUM-BASED CHEMOTHERAPY
Cisplatin represents standard treatment for advanced 
NSCLC. Nephrotoxicity, ototoxicity and neurotoxicity 
are the most common non-haematological toxicities 
attributed to cisplatin in addition to haematological 
ones. 
Carboplatin is responsible for lower incidence of 
nausea, nephrotoxicity and neurotoxicity, although 
safety remains an issue also due to its administration 
in combination with other myelotoxic agents. 
Retrospective analyses of platinum-based chemotherapy
In the last decade many data were collected from large 
randomised trials not selected for elderly patients.
No significant differences in terms of efficacy were 
shown in retrospective analysis from ECOG 5592 
comparing effects of two different platinum-based 
schedules in patients older than 70 years respect 
to younger counterpart. In terms of toxicity elderly 
patients had worse leukopenia and neuropsychiatric 
disorders[26]. ECOG 1594 trial compared four treatment 
combinations in first-line with no significant differences 
for RR and MST in retrospective subset analysis for the 
227 patients (20%) aged ≥ 70. Significant (P = 0.04) 
major grade 4 toxicities were reported in the elderly 
subgroup[27]. Always referring to retrospective analysis 
the Southwest Oncology Group (SWOG) 9509 trial, 
and the SWOG 9308 trial, documented no significant 
age influence on MST, TTP and toxicity[28]. 
In more recent years, the CALGB compared 
carboplatin plus paclitaxel with paclitaxel. MST was 
similar between patients aged > 70 and their younger 
counterpart. A secondary analysis evidenced a survival 
advantage for the doublet in the elderly patients[29].
TAX 326 compared first-line cisplatin plus vinorelbine 
or docetaxel. In the subset analysis considering patients 
aged ≥ 65 increase in survival was obtained with 
docetaxel plus cisplatin respect to vinorelbine/cisplatin. 
Lowest incidence in toxicity was registered for docetaxel 
plus carboplatin arm[30].
Comparing weekly paclitaxel or standard dose 
paclitaxel in combination with carboplatin in the elderly, 
the fractionated regimen produced higher RR, TTP and 
MST. Significant less neuropathy was encountered in 
the experimental arm[31-34] (Table 2).
Platinum-based chemotherapy: Prospectives studies 
Many prospective phase Ⅱ trials evaluating third-
generation cytotoxic agents with modified platinum-
based schedules were performed in the last 20 years. 
Cisplatin and gemcitabine combination was tested in 
four phase Ⅱ trials reaching an ORR around 40% and 
a MST of 10 mo[35-38]. At least three phase Ⅱ trials 
tested cisplatin/vinorelbine schedule with similar ORR 
and MST[39-41]. Both combinations demonstrated to 
be safe. Better results in terms of ORR and MST were 
demonstrated by Ohe et al[42] in patients aged ≥ 75 
years by adding docetaxel to weekly cisplatin[42,43].
In 2007 Gridelli et al[44] tested in the MILES 2P the 
feasibility of cisplatin with gemcitabine or vinorelbine in 
elderly patients. Both combinations were feasible and 
active with the former combination being the preferred 
one for a direct comparison with standard single-agent 
104 July 28, 2015|Volume 5|Issue 2|WJR|www.wjgnet.com
Table 1  Results from phase Ⅲ trials of advanced non-small-cell lung cancer in elderly patients: Non-platinum based chemotherapy
Ref. Regimen Age (yr) No. of patients RR (%) MST (mo)
Gridelli[11] Vinorelbine 70   76 20   6.5
vs 
Best Supportive Care   78 NA   4.8
Frasci et al[23] Vinorelbine 70   60 15   4.2
vs
Vinorelbine + Gemcitabine   60 22   6.7
Gridelli et al[24] Vinorelbine or 70 233 18   8.3
Gemcitabine 233 16   6.5
vs
Vinorelbine + Gemcitabine 232 21   6.9
Kudoh et al[22] Vinorelbine ≥ 70   91      9.9   9.9
vs
Docetaxel   88    22.7 14.3
Quoix et al[54] Vinorelbine or Gemcitabine ≥ 70 226 10.3
vs
Carboplatin/paclitaxel 225   6.2
Hainsworth et al[25] Docetaxel ≥ 65 171 17   5.1
vs
Docetaxel/gemcitabine 174 25   5.5
RR: Response rate; MST: Median survival time; NA: Not applicable.
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vs single agent arm. Considering QoL, role functioning 
and fatigue were worse in the doublet group than in 
single agent. Authors concluded that despite increased 
toxic effects for doublet, this should be considered as 
standard treatment in first line setting[54].
For the future better CDDP-based schedule in 
terms of activity and tolerability should be tested by 
direct comparison and considering emerging strong 
data about histology (Table 4).
TARGETED THERAPIES
Bevacizumab 
The SAIL study assessed the addition of bevacizumab 
to standard chemotherapy in terms of safety and 
efficacy in the first-line. When evaluating incidence 
of anti-VEGFR related side-effects in a planned 
analysis including elderly patients no difference was 
chemotherapy in this setting (Table 3).
Carboplatin plus vinorelbine combination was tested 
in two phase Ⅱ studies without any clinical benefit 
compared to standard treatment[45,46]. More favourable 
results were reported for the combination of low-dose 
carboplatin (AUC 4) and gemcitabine accompanied by 
acceptable toxicity[47].
Modified carboplatin/paclitaxel schedules reached 
in many trials 70% RR and 14 mo MST[10,48-53]. 
Recently IFCT-0501 confronted attenuated 
carboplatin-paclitaxel schedule vs standard single 
agent monotherapy. Combination and standard 
treatment showed respectively 10.3 and 6.2 mo in 
terms of OS. Regarding toxicity, grade 3-4 neutropenia 
and thrombocytopenia were 54.3% and 6.3% for 
doublet respect to 14.3% and 1% for single agent. 
Considering non-hematological toxicity, neuropathy 
resulted significantly more frequent in the doubletarm 
Table 2  Retrospective data analyses of elderly patients enrolled in phase Ⅲ trials with cisplatin- or carboplatin-based chemotherapy
Ref. Treatment Age (yr) No. of patients RR MST (mo) P  value
Nguyen et al[27] CDDP + GEM ≥ 70   53 15%   7.7 NS
< 70 207 29%   9.4
Kelly et al[28] CBDCA + TAX ≥ 70 117 NR   6.9 0.06
CDDP + VNR < 70 491 NR   8.6
Langer et al[26] CDDP + VP-16 ≥ 70   86    23.3%   8.5 NS
CDDP + TAX < 70 488    21.5%   9.1
Rocha Lima et al[32] CDDP + VBL ≥ 70   31 16%   5.7 NS
< 70 222 31%   8.0
Hensing et al[33] CBDCA + TAX ≥ 70   67 27%   7.1 NS
< 70 163 20%   7.8
Belani et al[30] CDDP + TXT ≥ 65 149 NR 12.6 NS
All ages 408 32% 11.3
CDDP + VNR ≥ 65 134 NR   9.9 NS
All ages 404 25% 10.1
CBDCA + TXT ≥ 65 118 NR   9.0 NS
All ages 406 24%   9.4
Belani et al[30] CBDCA + TAXw ≥ 70   70    25.7%   9.2 NR
< 70 147    28.6%   9.6
CBDCA + TAX ≥ 70   63 19%   7.7 NR
< 70 151    19.2% 11.4
Lilenbaum et al[29] CBDCA + TAX ≥ 70   77 36%   8.0 NS
< 70 207 30%   8.5
CDDP: Cisplatin; CBDCA: Carboplatin; TAX: Paclitaxel; TXT: Docetaxel; VNR: Vinorelbine; GEM: Gemcitabine; VBL: Vinblastine; VP-16: Etoposide; RR: 
Response rate; MST: Median survival time; S: Survival; NR: Not reported; NS: Not significant.
Table 3  Phase Ⅱ trials of cisplatin-based chemotherapy with third-generation agents and modified schedules or attenuated doses of 
cisplatin
Ref.  Regimen CDDP dose Age (yr) No.of patients RR MST (mo)
1Mattioli et al[39]   CDDP + VNR 25 mg/m2, weekly > 65 36    36% 11
Pereira et al[40]   CDDP + VNR 60-90 mg/m² > 70 44    50%      7.5
Buffoni et al[41]   CDDP + VNR 30 mg/m², day 1 and 8 ≥ 70 30    33%      7.4
Lippe et al[35]   CDDP + GEM 35 mg/m2, weekly ≥ 65 29    48% 10
Berardi et al[36]   CDDP + GEM 35 mg/m2, weekly ≥ 70 48 31.8%   9
Feliu et al[37]   CDDP + GEM 50 mg/m2 ≥ 70 46    35%    10.2
Moscetti et al[38]   CDDP + GEM 75 mg/m², day 2 ≥ 65 46 45.6% 15
Ohe et al[42] CDDP + TXT 25 mg/m2, weekly ≥ 75 33    52%    15.8
1Including 3 unfit patients; CDDP: Cisplatin; VNR: Vinorelbine; GEM: Gemcitabine; TXT: Docetaxel; RR: Response rate; MST: Median survival time; S: 
Survival.
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Table 4  Prospective trials of first line platinum-based 
chemotherapy in elderly patients affected by advanced non-
small-cell lung cancer
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encountered. OS (14.6 mo in both groups), TTP (8.2 
mo vs 7.6 mo), RR (49.3% vs 52.4%) and disease 
control rate (89.3% vs 88.4%) were similar in both 
arms[55].
The ARIES trial evaluated bevacizumab in clinical 
practice. Six hundred and fifty enrolled patients were 
older than 70 and experienced similar adverse events 
than total population except for arterial thromboembolic 
events (slightly increased in patients ≥ 70 years old). 
Median PFS and OS were similar in both subgroups[56].
EGFR tyrosine kinase inhibitors
Gefitinib/erlotinib: Gefitinib and erlotinib are re-
versible inhibitor of EGFR that competitively inhibits 
the binding of ATP. 
Antitumor activity of single-agent gefitinib in 
patients unselected for EGFR status has been tested 
in many trials. When gefitinib was dispensed in the 
second line setting in an unselected populations with 
NSCLC obtained 5.3 mo of MST[57]. 
In the subgroup of elderly patients gefitinib main-
tained its activity and good tolerance with no grade 
3 or 4 side effects experienced[58]. Cavina et al[59] 
reported encouraging efficacy data with only 10% of 
grade 3 skin toxicity and 3% of diarrhoea. Gridelli et 
al[60] reported in the same setting of patients similar 
MST and favourable safety profile. Cappuzzo et al[61] 
observed reported 5 mo MST and mild side effects. 
Hotta et al[62] studied gefitinib on patients aged ≥ 75 
years: RR 17%; SD 43%; MST 7.6 mo. Grade 3-4 
toxicity was encountered in 9% of patients (Table 5). 
Gefitinib addition to chemotherapy has been 
tested. Stinchcombe et al[63] combined weekly 
docetaxel plus daily oral gefitinib: RR 31%, MST 6.5 
mo, 1-year survival 27%. The schedule resulted in 
excessive toxicity for elderly patients[63]. Bepler et al[64] 
added daily gefitinib to three-weekly docetaxel: RR 
38%, SD 24%, MST 12.4 mo, and 1-year survival of 
60%. Better tolerance was reported even if adverse 
effects required hospitalization in 6 patients[64]. A 
phase Ⅱ trial evaluated gefitinib with vinorelbine or 
gemcitabine. Vinorelbine plus gefitinib produced 72% 
of grade 3-4 neutropenia and 3 treatment-related 
deaths while the association with gemcitabine reported 
a lower activity (RR 5.7%, SD 14%, MST 9.1 mo) but 
a better safety profile (grade 3-4 neutropenia 11.4%; 
thrombocytopenia 8.6%, asthenia and diarrhoea 
5.7%)[65,66] (Table 6).
At least three single-arm trials tested the role 
of gefitinib in patients with EGFR mutation positive 
tumors. A phase Ⅱ study conducted with erlotinib in 
patients older than 70 years in Ⅰ line setting, showing 
encouraging activity (RR of 10.9%, SD of 54.5%) 
and MST (10.5 mo). Adverse events were mild. EGFR 
mutations have been detected in 3 out of 5 responsive 
patients to erlotinib treatment[67]. Erlotinib improved also 
QoL and many disease related symptoms[68] (Table 7). 
The EURTAC trial population with its median age 
of 65 years old represent an older population respect 
to common trial population. This trial showed that 
erlotinib yielded a longer progression-free survival than 
chemotherapy[69].
An age-unspecified trial in patients not selected for 
mutation status, the BR21, showed that in a second 
or third line setting, erlotinib improves survival but at 
a cost to older patients. Although older and younger 
patients achieved comparable PFS, OS and RRs, older 
patients suffered worse toxicity due to rash, fatigue 
and dehydration[70]. 
Erlotinib performed better than vinorelbine in a 
subgroup of EGFR mutation positive elderly patients 
as shown in a prospective phase Ⅱ trial while failed 
to gain advantage when added to gemcitabine or 
compared to it in molecularly not selected elderly 
patients[71,72]. 
SECOND-LINE CHEMOTHERAPY
Retrospective subgroup analysis on elderly patients 
from phase Ⅲ trials testing pemetrexed vs docetaxel 
obtained: TTP 4.6 mo vs 2.9 mo, MST 9.5 mo vs 7.7 
mo, 12-mo survival was 20.4% vs 23.1%, 24-mo 
survival 6.1% vs 10.6%, respectively. Neutropenia, 
febrile neutropenia and anemia were more consistent 
in docetaxel arm[73]. Second-line cytotoxic therapy 
appeared feasible for good performance status elderly 
patients.
Pemetrexed produced a more favourable toxicity 
profile compared to docetaxel. In a phase Ⅱ trial a 
modified schedule of docetaxel (37.5 mg/m2 on days 
1 and 8 every three weeks) reported encouraging 
activity and acceptable toxicity profile[74]. 
Ref. Regimen Phase Age 
(yr)
No. of 
patients
Efficacy
Gridelli et al[44] CDDP + GEM Ⅰ/Ⅱ ≥ 70 159 OS 43.6 wk
PFS 25.3 wk 
RR 43.5%
CDDP + VNR OS 33.1 wk
PFS 21.1 wk 
RR 36.1%
Abe et al[43] CDDP + DOC Ⅲ > 70 221 OS 13.3 wk 
vs OS 17.3 wk
DOC
Biesma et al[53] CARBO + GEM Ⅲ ≥ 70 181 OS 8.6 mo
vs RR 27%
CARBO + PAC OS 6.9 mo
RR 19%
Quoix et al[54] GEM or VNR Ⅲ ≥ 70 451 OS 6.2 mo
vs RR 10.9%
CARBO + PAC OS 10.3 mo
RR 29.5% 
CDDP: Cisplatin; VNR: Vinorelbine; GEM: Gemcitabine; CARBO: Carboplatin; 
RR: Response rate; OS: Overall survival. 
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Second-line cytotoxic therapy appeared feasible for 
good performance status elderly patients.
A recent retrospective review of elderly patients 
receiving a second line therapy analyzing 293 young 
patients (age < 70) and 168 patients (> 70) treated 
with second-line treatment (both chemotherapy and 
EGFR TKIs) showed no differences in both efficacy and 
toxicity between the two age group[75].
GERIATRIC ASSESSMENT
As elderly patients represent a very heterogeneous 
group, their functional status cannot be established only 
basing on chronological parameters. Comprehensive 
Geriatric Assessment (CGA) is a multidisciplinary and 
multidimensional approach including many items: co-
existing diseases, socioeconomic status, nutritional 
status, medicine intake, and the presence of geriatric 
syndromes. 
Many works demonstrated to add very useful in-
formations regarding functional assessment of elderly 
patients permitting better evaluation in terms of pro-
gnostic aspects[76]. 
A meta-analysis based on 28 trials demonstrated 
that CGA, when applied together with geriatric inter-
ventions is capable to reduce early re-hospitalization 
and mortality. Nowadays no phase Ⅲ randomized 
trials are available.
More recent studies attributed to many CGA 
issues the power to predict the risk of chemotherapy 
toxicity[77]. 
Puts et al[78] reported data on CGA in cancer patients 
collected from 73 trials. Six reported a significant 
association with chemotherapy toxicity, 8 demonstrated 
association with mortality and other 2 a change of 
treatment indications after CGA assessment. CGA is 
recommended by the International Society of Geriatric 
Oncology (SIOG) and the EORTC[78].
CONCLUSION
NSCLC remains the major cause of cancer-related 
Table 5  Retrospective analyses of gefitinib in the treatment of unselected elderly patients with advanced non-small-cell lung cancer
Ref. Previous chemotherapy Age (yr) No. of 
patients
RR (%) SD (%) MST (mo) Toxicity G ≥ 3
Copin et al[58]  Yes (61%) ≥ 70 61 2 (3) 16 (26) NR None
 No (39%)
Cavina et al[59]    Yes (64.5%) ≥ 70 31 0 (0) 18 (58) 3.0 G3 skin 10%
    No (35.5%) G3 diarrhoea 3%
Gridelli et al[60]    Yes (94.5%) ≥ 70 18 0 (0)   2 (11) 4.4 None
  No (5.5%)
Cappuzzo et al[61]   Yes (100%) ≥ 70 40 2 (5) 18 (45) 5.0 G4 diarrhoea 2.5%
Hotta et al[62] Yes (57%) ≥ 75 92 16 (17) 40 (43) 7.6 G3-4 toxicity 9%
 No (43%)
RR: Response rate; SD: Stable disease; MST: Median survival time; G: Grade; NR: Not reported. 
Table 6  Studies with gefitinib (250 mg/d) plus chemotherapy in the treatment of elderly patients (age ≥ 70 years) with advanced 
non-small-cell lung cancer
Ref. Treatment Study phase No. of 
patients
RR (%) SD (%) MST 
(mo)
Toxicity G ≥ 3
Stinchcombe et al[63] TXT 30-36 mg/m², 
days 1, 8, 15, Q4W
Ⅰ/Ⅱ 26   8 (31) -   6.5 G3-5 toxicity 
42%
Bepler et al[64] TXT 75 mg/m², day 1, Q3W Ⅱ 21   8 (38)   5 (24) 12.4 G3-4 toxicity 28.5%
Scagliotti et al[65] GEM 1200 mg/m², days 1, 8, Q3W Ⅱ 
Random
35    2 (5.7) 14 (40)   9.1 G3-4 neutropenia 11.4%
vs
VNR 30 mg/m², days 1, 8, Q3W 25 0 (0) 11 (44) 12.2 G3-4 neutropenia 72%
3 toxic deaths
RR: Response rate; SD: Stable disease; MST: Median survival time; G: Grade; TXT: Docetaxel; GEM: Gemcitabine; VNR: Vinorelbine; Q4W: Every 4 wk; 
Q3W: Every 3 wk; Random: Randomised. 
Table 7  Phase Ⅱ study of single-agent erlotinib in the treatment of advanced non-small-cell lung cancer elderly patients
Ref. Previous chemotherapy Age (yr) No. of 
patients
RR (%) SD (%) MST (mo) Toxicity G ≥ 3
Jackman et al[67] No (100%) ≥ 70 58 6 (10.9) 30 (54.5) 10.5 G ≥ 3 toxicity 30%
RR: Response rate; SD: Stable disease; MST: Median survival time; G: Grade. 
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deaths.
Altered organ functions and higher incidence of 
co-morbidities usually affect treatment decisions. 
Platinum-based treatment while is a mainstay for 
advanced NSCLC in younger patients is still considered 
questionable for elderly patients due to higher risk of 
toxicity. However many retrospective subset analyses 
demonstrated only minimal or none differences 
between elderly and younger counterpart patients.
Dedicated trials for elderly population are anyway 
needed. Research must be empowered looking for 
new tools and items capable of better define “biological” 
and “chronological” aspects of ageing. At the same 
time several treatment options should still be evaluated 
as for example: doublets with and without platinum, 
maintenance strategies and biologic agents[73].
A third-generation agent given alone is at the time 
the recommended option for elderly advanced NSCLC 
patients[79-81]. 
The choice for the best agent should consider 
together expected toxicities, pharmacokinetics aspects, 
liver-kidney function and co-existing illnesses. 
Doublets employing platinum could be consider 
a valid indication for fit elderly patients with normal 
organ function. Each patient should receive a functional 
assessment at baseline in order to better define the 
therapeutic options.
Considering continuous elucidation of mechanisms 
that contribute to the malignant phenotype and 
subsequent molecular targets for anticancer therapy 
several biologic agents have been introduced in 
the treatment of NSCLC and many are still under 
investigation. 
Trials performed with new targeted agents in 
molecularly selected younger population evidenced 
very good toxicity profile. So new biologic drugs are 
better candidates than chemotherapy to be tested in 
elderly patients. Gefitinib and erlotinib have already 
proven to be effective in chemotherapy-refractory 
NSCLC patients. Their mild toxicity profile, experienced 
in elderly patients with advanced disease, makes them 
some of the best candidates to test prospectively as 
single-agent first-line treatment in molecularly selected 
elderly population, as an alternative to chemotherapy. 
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